| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TUSC2 |
| Uniprot No | O75896 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-110aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMGASGSK ARGLWPFASA AGGGGSEAAG AEQALVRPRG RAVPPFVFTR RGSMFYDEDG DLAHEFYEET IVTKNGQKRA KLRRVHKNLI PQGIVKLDHP RIHVDFPVIL YEV |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TUSC2重组蛋白的3篇代表性文献摘要：
1. **《TUSC2重组蛋白通过诱导凋亡抑制肺癌生长的机制研究》**
- **作者**：Ji, H. 等
- **摘要**：研究通过体外和体内实验证明，重组TUSC2蛋白能激活线粒体凋亡通路，抑制非小细胞肺癌细胞增殖，并增强顺铂的化疗敏感性，提示其作为肿瘤治疗靶点的潜力。
2. **《脂质体纳米颗粒递送TUSC2重组蛋白的临床前评估》**
- **作者**：Roth, J.A. 等
- **摘要**：开发了一种脂质体包裹的TUSC2重组蛋白递送系统，在小鼠模型中显著抑制肺癌转移，并通过调控PI3K/AKT通路抑制肿瘤生长，为后续临床试验奠定基础。
3. **《TUSC2重组蛋白通过免疫调节增强抗肿瘤反应》**
- **作者**：Zhang, X. 等
- **摘要**：发现TUSC2重组蛋白能激活树突状细胞并促进T细胞浸润，在黑色素瘤模型中联合PD-1抑制剂显著延长生存期，揭示了其免疫调节功能。
(注：以上文献信息为示例，实际引用请核对具体论文及发表信息。)
**Background of TUSC2 Recombinant Protein**
TUSC2 (tumor suppressor candidate 2), also known as FUS1. is a gene located on human chromosome 3p21.3. a region frequently deleted or mutated in various cancers, including lung, breast, and ovarian cancers. It encodes a mitochondrial protein implicated in tumor suppression, apoptosis, and regulation of cellular proliferation. TUSC2 functions as a scaffold protein, interacting with signaling pathways such as AKT/mTOR and STAT3. thereby modulating cell survival, DNA repair, and immune responses. Loss or inactivation of TUSC2 is associated with cancer progression, metastasis, and resistance to therapy.
Recombinant TUSC2 protein is engineered through molecular cloning and expression systems (e.g., *E. coli* or mammalian cells) to produce purified, bioactive protein for research and therapeutic applications. Its recombinant form retains functional domains critical for tumor-suppressive activity, such as binding to oncogenic kinases or promoting pro-apoptotic signals. Studies highlight its potential in cancer treatment, either as a standalone agent or in combination with chemotherapy or immunotherapy. For example, intravenous delivery of TUSC2 recombinant protein or gene therapy vectors (e.g., nanoparticles, liposomes) has shown efficacy in preclinical models by restoring apoptosis in cancer cells and inhibiting tumor growth.
Current research focuses on optimizing delivery mechanisms to overcome poor cellular uptake and short half-life *in vivo*. Clinical trials, particularly in non-small cell lung cancer (NSCLC), have explored TUSC2-based therapies, underscoring its role as a promising therapeutic target. However, challenges remain in achieving targeted delivery and minimizing off-target effects. Further investigation into its molecular interactions and synergistic combinations may unlock broader clinical applications.
×
